Cefpiromeの基礎的, 臨床的検討 LABORATORY AND CLINICAL STUDIES ON CEFPIROME

Access this Article

Author(s)

Abstract

新フェム系抗生剤cefpiromeの基礎的, 臨床的検討を行った。腎不全患者9例にcefpirome 1gを静注し, その体内動態を検討した。透析時及び非透析時の静注後5分値は, それぞれ平均101.6, 103.9μg/ml. β相における半減期 (T<SUB>1/2</SUB>β) は平均4.5, 19.8時間, 血漿中濃度一時間線下面積 (AUC<SUB>0~∞</SUB>) は平均287, 1762μg・h/rnlであった。<BR>臨床的検討は, 肺炎7例, 慢性気管支炎1例, 急性腎盂炎1例, 急性腎盂腎炎1例を対象として行い, マイコプラズマ肺炎2例およびリウマチ性問質性肺炎 (疑) の計3例は除外した。臨床効果は著効5例・有効4例, やや有効1例であり, 有効率90.0%であった。細菌学的効果は, 起炎菌の明らかなものは全て菌消失を認めた。自他覚的副作用は全例に認められなかったが, 2例に臨床検査値の異常を認めた。

We performed laboratory and clinical studies on cefpirome (CPR), a new cephem antibiotic, with the following results.<BR>We investigated the pharmacokinetics of the drug in nine patients with renal failure after intravenous administration of 1g. The mean plasma concentration of CPR, administered over 5 min, with and without hemodialysis, was 101.6 and 103.9μg/ml. The mean values of T<SUB>1/2</SUB> (β) in plasma were 4.5 and 19.8 h, and tht. AUCs were 287 and 1762μgh/ml.<BR>The clinical efficacy of CPR was studied in 10 patients: 7 with pneumonia, and 1 each with chronic bronchitis, acute pyelitis and acute pyelonephritis, 2 with mycoplasma pneumonia and 1 with rheumatic pneumonia having been excluded as unevaluable.<BR>The clinical response was excellent in 5 cases, good in 4 and fair in 1, with an overall efficacy rate of 90.0%.<BR>Bacteriologically, all causative pathogens were eradicated.<BR>No side-effects were noted, though abnormal laboratory findings were observed in two patients.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 39(Supplement1), 198-204, 1991

    Japanese Society of Chemotherapy

Codes

Page Top